- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Marlborough Today
By the People, for the People
Truist Financial Trims Boston Scientific Price Target
Brokerage firm cites market conditions in reducing price target for medical device maker.
Apr. 18, 2026 at 9:50am
Got story updates? Submit your updates here. ›
Truist Financial's price target reduction for Boston Scientific reflects broader market conditions impacting the medical device industry.Marlborough TodayTruist Financial has lowered its price target for Boston Scientific (NYSE:BSX) from $92.00 to $90.00 per share, while maintaining a 'buy' rating on the medical equipment provider's stock. The revised target comes amid broader market volatility and economic uncertainty.
Why it matters
Boston Scientific is a major player in the medical device industry, with a diverse portfolio of products used in minimally invasive procedures. Analyst price targets and ratings can influence investor sentiment and stock performance, so this update from Truist Financial provides insight into how the company is viewed by the investment community.
The details
In a report issued on Wednesday, Truist Financial analysts cited the current market environment as the primary reason for reducing Boston Scientific's price target, from $92.00 to $90.00 per share. However, the brokerage firm maintained its 'buy' rating on the stock. This follows several other recent analyst actions, including Needham & Company reaffirming a 'buy' rating with a $97.00 target, while Mizuho cut its price objective from $115.00 to $90.00.
- The Truist Financial report was issued on Wednesday, April 18, 2026.
The players
Boston Scientific
A global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Headquartered in Marlborough, Massachusetts.
Truist Financial
A major brokerage and financial services firm that provides research coverage and analysis on Boston Scientific and other public companies.
The takeaway
This price target adjustment from Truist Financial reflects the broader market volatility and economic uncertainty impacting the medical device industry. However, the firm's 'buy' rating suggests it still sees upside potential in Boston Scientific's stock, despite the modest target reduction.
